Cargando…

PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered (64)Cu-Radiolabeled Peptide Inhibitor()()

The potential of PACE4 as a pharmacological target in prostate cancer has been demonstrated as this proprotein convertase is strongly overexpressed in human prostate cancer tissues and its inhibition, using molecular or pharmacological approaches, results in reduced cell proliferation and tumor prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Couture, Frédéric, Levesque, Christine, Dumulon-Perreault, Véronique, Ait-Mohand, Samia, D’Anjou, François, Day, Robert, Guérin, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235008/ https://www.ncbi.nlm.nih.gov/pubmed/25220591 http://dx.doi.org/10.1016/j.neo.2014.07.010

Ejemplares similares

Comparative study of (64)Cu/NOTA-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14) monomer and dimers for prostate cancer PET imaging
por: Fournier, Patrick, et al.
Publicado: (2012)

(64)Cu-DOTHA(2)-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window
por: Milot, Marie-Christine, et al.
Publicado: (2022)

Theranostic (64)Cu-DOTHA(2)-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
por: Milot, Marie-Christine, et al.
Publicado: (2023)

Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity
por: Couture, Frédéric, et al.
Publicado: (2015)

[(68)Ga]Ga-4HMSA a promising new PET tracer for imaging inflammation
por: Kahn Ali, Shigufa, et al.
Publicado: (2021)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
por: Alnahwi, Aiman H., et al.
Publicado: (2020)

Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug
por: Kwiatkowska, Anna, et al.
Publicado: (2019)

Design, Synthesis, and Cytotoxicity Assessment of [(64)Cu]Cu-NOTA-Terpyridine Platinum Conjugate: A Novel Chemoradiotherapeutic Agent with Flexible Linker
por: Khosravifarsani, Meysam, et al.
Publicado: (2021)

In vivo behavior of [(64)Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer
por: Khosravifarsani, Meysam, et al.
Publicado: (2022)

(68)Ga-DOTATATE Prepared from Cyclotron-Produced (68)Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients
por: Tremblay, Sébastien, et al.
Publicado: (2023)

The Multi-Leu Peptide Inhibitor Discriminates Between PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate Cancer Cells
por: Levesque, Christine, et al.
Publicado: (2012)

Synthesis of DOTA-pyridine chelates for (64)Cu coordination and radiolabeling of αMSH peptide
por: Yang, Hua, et al.
Publicado: (2021)

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation
por: Levesque, Christine, et al.
Publicado: (2015)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

Early diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers
por: Habashi, Maram, et al.
Publicado: (2022)

Potential Production of Theranostic Boron Nitride Nanotubes ((64)Cu-BNNTs) Radiolabeled by Neutron Capture
por: Silva, Wellington Marcos, et al.
Publicado: (2021)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Metabolic efficiency with fast spiking in the squid axon
por: Moujahid, Abdelmalik, et al.
Publicado: (2012)

Energy demands of diverse spiking cells from the neocortex, hippocampus, and thalamus
por: Moujahid, Abdelmalik, et al.
Publicado: (2014)

Antibody and Nanobody Radiolabeling with Copper-64: Solid vs. Liquid Target Approach
por: Hrynchak, Ivanna, et al.
Publicado: (2023)

PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer
por: Couture, Frédéric, et al.
Publicado: (2022)

Evaluation of PACE4 isoforms as biomarkers in thyroid cancer
por: Fradet, Laurent, et al.
Publicado: (2018)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target()
por: Longuespée, Rémi, et al.
Publicado: (2014)

Chelation of Theranostic Copper Radioisotopes with S-Rich Macrocycles: From Radiolabelling of Copper-64 to In Vivo Investigation
por: Tosato, Marianna, et al.
Publicado: (2022)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Human SHQ1 variants R335C and A426V lead to severe ribosome biogenesis defects when expressed in yeast
por: Alidou-D’Anjou, Ismaël, et al.
Publicado: (2023)

The Pace of Cultural Evolution
por: Perreault, Charles
Publicado: (2012)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

PET Imaging of VEGFR with a Novel (64)Cu-Labeled Peptide
por: Hu, Kuan, et al.
Publicado: (2020)

Radiolabelled peptides for oncological diagnosis
por: Laverman, Peter, et al.
Publicado: (2012)

Radiolabeled Peptides and Antibodies in Medicine
por: Kręcisz, Paweł, et al.
Publicado: (2020)

Targeting telomerase with radiolabeled inhibitors
por: Waghorn, Philip A., et al.
Publicado: (2017)

Process to Remove the Size Variants Contained in the Antibody–Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64
por: Yoshii, Yukie, et al.
Publicado: (2023)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Self-paced part-list cuing
por: Wallner, Lisa, et al.
Publicado: (2021)

Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer
por: Mekdad, Nawel, et al.
Publicado: (2022)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u7ps1kqe6o71l230pallcqu5r5